A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer (Q33398693)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Thomas Seufferlein

11

object named as

Thomas Seufferlein

0 references

Günter Klöppel

10

object named as

Günter Klöppel

0 references

Wolff Schmiegel

7

object named as

Wolff Schmiegel

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Andre Mihaljevic

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Peter Büchler

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jan Harder

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ralf Hofheinz

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michael Gregor

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Stephan Kanzler

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Volker Heinemann

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Esther Endlicher

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michael Geissler

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

8 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661037

21 June 2018

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661037

21 June 2018

PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661037

21 June 2018

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661037

21 June 2018

Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661037

21 June 2018

Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661037

21 June 2018

Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661037

21 June 2018

Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661037

21 June 2018

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661037

21 June 2018

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661037

21 June 2018

Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661037

21 June 2018

Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661037

21 June 2018

Clinical pharmacokinetics of capecitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661037

21 June 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661037

21 June 2018

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661037

21 June 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2661037

21 June 2018

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2482-9-1

21 January 2018

Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2482-9-1

21 January 2018

Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2482-9-1

21 January 2018

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2482-9-1

21 January 2018

Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2482-9-1

21 January 2018

Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu

1 reference

https://api.crossref.org/works/10.1186%2F1471-2482-9-1

21 January 2018

Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire

1 reference

https://api.crossref.org/works/10.1186%2F1471-2482-9-1

21 January 2018

Differences in Survival by Histologic Type of Pancreatic Cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2482-9-1

21 January 2018

Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19133157

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2482-9-1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33398693&oldid=2195322785"